[8-K] Kiora Pharmaceuticals, Inc. Reports Material Event
Kiora Pharmaceuticals, Inc. reported via an 8-K that on August 8, 2025 it issued a press release announcing financial results for the quarter ended June 30, 2025 and provided an update on its clinical development progress. The press release is furnished as Exhibit 99.1 and an Inline XBRL cover page is included as Exhibit 104. The filing states that the furnished information, including Exhibit 99.1, is not deemed "filed" under Section 18 and is not incorporated by reference into other Securities Act or Exchange Act filings except where expressly stated.
The report is signed by Melissa Tosca, Chief Financial Officer. No financial line-item figures or clinical data are presented within the 8-K text itself; readers must refer to Exhibit 99.1 for the detailed press release content.
Kiora Pharmaceuticals, Inc. ha comunicato tramite un modulo 8-K che in data 8 agosto 2025 ha diffuso un comunicato stampa con i risultati finanziari del trimestre chiuso al 30 giugno 2025 e ha fornito un aggiornamento sui progressi del suo sviluppo clinico. Il comunicato 猫 fornito come Exhibit 99.1 e nella pratica 猫 inclusa una copertina Inline XBRL quale Exhibit 104. La relazione precisa che le informazioni fornite, incluso l'Exhibit 99.1, non sono considerate "filed" ai sensi della Section 18 e non sono incorporate per riferimento in altri documenti presentati ai sensi del Securities Act o dell'Exchange Act, salvo diversa indicazione espressa.
Il rapporto 猫 sottoscritto da Melissa Tosca, direttrice finanziaria (Chief Financial Officer). Nel testo dell'8-K non sono riportati importi numerici delle voci finanziarie n茅 dati clinici; per il contenuto dettagliato del comunicato va consultato l'Exhibit 99.1.
Kiora Pharmaceuticals, Inc. inform贸 mediante un formulario 8-K que el 8 de agosto de 2025 emiti贸 un comunicado de prensa con los resultados financieros del trimestre concluido el 30 de junio de 2025 y proporcion贸 una actualizaci贸n sobre el avance de su desarrollo cl铆nico. El comunicado se adjunta como Exhibit 99.1 y se incluye una portada Inline XBRL como Exhibit 104. La presentaci贸n indica que la informaci贸n suministrada, incluido el Exhibit 99.1, no se considera "filed" seg煤n la Section 18 y no se incorpora por referencia en otros documentos presentados bajo el Securities Act o el Exchange Act, salvo que se indique expresamente lo contrario.
El informe est谩 firmado por Melissa Tosca, directora financiera (Chief Financial Officer). En el texto del 8-K no se incluyen cifras detalladas por partida ni datos cl铆nicos; para el detalle del comunicado debe consultarse el Exhibit 99.1.
Kiora Pharmaceuticals, Inc.電� 8-K毳� 韱淀暣 2025雲� 8鞗� 8鞚检棎 2025雲� 6鞗� 30鞚茧 膦呺霅� 攵勱赴 鞁れ爜鞚� 氚滍憸頃橂姅 氤措弰鞛愲毳� 氚滍枆頃橁碃 鞛勳儊 臧滊皽 歆勴枆靸來櫓鞚� 鞐呺嵃鞚错姼頄堧嫟瓿� 瓿奠嫓頄堨姷雼堧嫟. 頃措嫻 氤措弰鞛愲電� Exhibit 99.1搿� 鞝滉车霅橂┌, Inline XBRL 響滌 韼橃澊歆�電� Exhibit 104搿� 韽暔霅橃柎 鞛堨姷雼堧嫟. 鞝滌稖靹滊鞐愲姅 鞝滉车霅� 鞝曤炒(氚� Exhibit 99.1 韽暔)臧� Section 18鞐� 霐半澕 "filed"搿� 臧勳＜霅橃 鞎婌溂氅�, 氇呾嫓鞝侅溂搿� 鞏戈笁霅� 瓴届毎毳� 鞝滌櫢頃橁碃電� 雼るジ Securities Act 霕愲姅 Exchange Act 鞝滌稖靹滊鞐� 彀胳“搿� 韱淀暕霅橃 鞎婋姅雼り碃 氇呾嫓霅橃柎 鞛堨姷雼堧嫟.
氤搓碃靹滊姅 鞛毂呾瀯鞛� Melissa Tosca臧� 靹滊獏頄堨姷雼堧嫟. 8-K 氤鸽鞐愲姅 臧滊硠 鞛 頃 靾橃箻雮� 鞛勳儊 雿办澊韯瓣皜 韽暔霅橃柎 鞛堨 鞎婌溂氙�搿� 靸侅劯頃� 氤措弰鞛愲 雮挫毄鞚� Exhibit 99.1鞚� 彀胳“頃挫暭 頃╇媹雼�.
Kiora Pharmaceuticals, Inc. a d茅clar茅 via un formulaire 8-K que, le 8 ao没t 2025, elle a publi茅 un communiqu茅 de presse annon莽ant les r茅sultats financiers du trimestre clos le 30 juin 2025 et fournissant une mise 脿 jour sur l'avancement de son d茅veloppement clinique. Le communiqu茅 est fourni en tant que Exhibit 99.1 et une page de couverture Inline XBRL est incluse en tant que Exhibit 104. Le d茅p么t pr茅cise que les informations fournies, y compris l'Exhibit 99.1, ne sont pas r茅put茅es "filed" au titre de la Section 18 et ne sont pas incorpor茅es par r茅f茅rence dans d'autres documents d茅pos茅s en vertu du Securities Act ou de l'Exchange Act, sauf indication expresse contraire.
Le rapport est sign茅 par Melissa Tosca, directrice financi猫re (Chief Financial Officer). Le texte du 8-K ne contient pas de montants d茅taill茅s ligne par ligne ni de donn茅es cliniques ; pour le contenu complet du communiqu茅, se r茅f茅rer 脿 l'Exhibit 99.1.
Kiora Pharmaceuticals, Inc. teilte in einem Formular 8-K mit, dass es am 8. August 2025 eine Pressemitteilung ver枚ffentlichte, in der die Finanzergebnisse f眉r das Quartal zum 30. Juni 2025 bekanntgegeben wurden, und gab ein Update zu seinem klinischen Entwicklungsfortschritt. Die Pressemitteilung wird als Exhibit 99.1 bereitgestellt; eine Inline-XBRL-Titelseite ist als Exhibit 104 beigef眉gt. In der Einreichung hei脽t es, dass die bereitgestellten Informationen, einschlie脽lich des Exhibit 99.1, nach Section 18 nicht als "filed" gelten und, sofern nicht ausdr眉cklich angegeben, nicht durch Verweis in andere Unterlagen nach dem Securities Act oder dem Exchange Act einbezogen werden.
Der Bericht ist von Melissa Tosca, Chief Financial Officer, unterzeichnet. Im Text des 8-K sind keine einzelnen Finanzposten oder klinischen Daten enthalten; f眉r die vollst盲ndigen Details ist das Exhibit 99.1 heranzuziehen.
- None.
- None.
Insights
TL;DR: Routine 8-K furnishing a press release on Q2 2025 results and a clinical update; no financial details are included in the filing itself.
The filing formally notifies investors that Kiora furnished a press release on August 8, 2025 announcing results for the quarter ended June 30, 2025 and clinical development progress. The 8-K supplies exhibit identifiers but contains no financial totals, metrics, or forward-looking statements. The disclosure approach鈥攆urnishing versus filing鈥攍imits legal incorporation by reference, which is a common procedural choice. For material financial assessment, the attached Exhibit 99.1 must be reviewed.
TL;DR: The 8-K notes a clinical development update was announced but provides no trial data or specifics within the filing.
The document confirms Kiora provided a clinical development update as part of the August 8, 2025 press release. No trial names, phase progression, endpoints, enrollment updates, regulatory interactions, or data are included in the 8-K text. As such, the filing signals communication activity but contains no clinical details that would permit technical evaluation of program progress or timelines; the press release (Exhibit 99.1) is the necessary source for substantive clinical information.
Kiora Pharmaceuticals, Inc. ha comunicato tramite un modulo 8-K che in data 8 agosto 2025 ha diffuso un comunicato stampa con i risultati finanziari del trimestre chiuso al 30 giugno 2025 e ha fornito un aggiornamento sui progressi del suo sviluppo clinico. Il comunicato 猫 fornito come Exhibit 99.1 e nella pratica 猫 inclusa una copertina Inline XBRL quale Exhibit 104. La relazione precisa che le informazioni fornite, incluso l'Exhibit 99.1, non sono considerate "filed" ai sensi della Section 18 e non sono incorporate per riferimento in altri documenti presentati ai sensi del Securities Act o dell'Exchange Act, salvo diversa indicazione espressa.
Il rapporto 猫 sottoscritto da Melissa Tosca, direttrice finanziaria (Chief Financial Officer). Nel testo dell'8-K non sono riportati importi numerici delle voci finanziarie n茅 dati clinici; per il contenuto dettagliato del comunicato va consultato l'Exhibit 99.1.
Kiora Pharmaceuticals, Inc. inform贸 mediante un formulario 8-K que el 8 de agosto de 2025 emiti贸 un comunicado de prensa con los resultados financieros del trimestre concluido el 30 de junio de 2025 y proporcion贸 una actualizaci贸n sobre el avance de su desarrollo cl铆nico. El comunicado se adjunta como Exhibit 99.1 y se incluye una portada Inline XBRL como Exhibit 104. La presentaci贸n indica que la informaci贸n suministrada, incluido el Exhibit 99.1, no se considera "filed" seg煤n la Section 18 y no se incorpora por referencia en otros documentos presentados bajo el Securities Act o el Exchange Act, salvo que se indique expresamente lo contrario.
El informe est谩 firmado por Melissa Tosca, directora financiera (Chief Financial Officer). En el texto del 8-K no se incluyen cifras detalladas por partida ni datos cl铆nicos; para el detalle del comunicado debe consultarse el Exhibit 99.1.
Kiora Pharmaceuticals, Inc.電� 8-K毳� 韱淀暣 2025雲� 8鞗� 8鞚检棎 2025雲� 6鞗� 30鞚茧 膦呺霅� 攵勱赴 鞁れ爜鞚� 氚滍憸頃橂姅 氤措弰鞛愲毳� 氚滍枆頃橁碃 鞛勳儊 臧滊皽 歆勴枆靸來櫓鞚� 鞐呺嵃鞚错姼頄堧嫟瓿� 瓿奠嫓頄堨姷雼堧嫟. 頃措嫻 氤措弰鞛愲電� Exhibit 99.1搿� 鞝滉车霅橂┌, Inline XBRL 響滌 韼橃澊歆�電� Exhibit 104搿� 韽暔霅橃柎 鞛堨姷雼堧嫟. 鞝滌稖靹滊鞐愲姅 鞝滉车霅� 鞝曤炒(氚� Exhibit 99.1 韽暔)臧� Section 18鞐� 霐半澕 "filed"搿� 臧勳＜霅橃 鞎婌溂氅�, 氇呾嫓鞝侅溂搿� 鞏戈笁霅� 瓴届毎毳� 鞝滌櫢頃橁碃電� 雼るジ Securities Act 霕愲姅 Exchange Act 鞝滌稖靹滊鞐� 彀胳“搿� 韱淀暕霅橃 鞎婋姅雼り碃 氇呾嫓霅橃柎 鞛堨姷雼堧嫟.
氤搓碃靹滊姅 鞛毂呾瀯鞛� Melissa Tosca臧� 靹滊獏頄堨姷雼堧嫟. 8-K 氤鸽鞐愲姅 臧滊硠 鞛 頃 靾橃箻雮� 鞛勳儊 雿办澊韯瓣皜 韽暔霅橃柎 鞛堨 鞎婌溂氙�搿� 靸侅劯頃� 氤措弰鞛愲 雮挫毄鞚� Exhibit 99.1鞚� 彀胳“頃挫暭 頃╇媹雼�.
Kiora Pharmaceuticals, Inc. a d茅clar茅 via un formulaire 8-K que, le 8 ao没t 2025, elle a publi茅 un communiqu茅 de presse annon莽ant les r茅sultats financiers du trimestre clos le 30 juin 2025 et fournissant une mise 脿 jour sur l'avancement de son d茅veloppement clinique. Le communiqu茅 est fourni en tant que Exhibit 99.1 et une page de couverture Inline XBRL est incluse en tant que Exhibit 104. Le d茅p么t pr茅cise que les informations fournies, y compris l'Exhibit 99.1, ne sont pas r茅put茅es "filed" au titre de la Section 18 et ne sont pas incorpor茅es par r茅f茅rence dans d'autres documents d茅pos茅s en vertu du Securities Act ou de l'Exchange Act, sauf indication expresse contraire.
Le rapport est sign茅 par Melissa Tosca, directrice financi猫re (Chief Financial Officer). Le texte du 8-K ne contient pas de montants d茅taill茅s ligne par ligne ni de donn茅es cliniques ; pour le contenu complet du communiqu茅, se r茅f茅rer 脿 l'Exhibit 99.1.
Kiora Pharmaceuticals, Inc. teilte in einem Formular 8-K mit, dass es am 8. August 2025 eine Pressemitteilung ver枚ffentlichte, in der die Finanzergebnisse f眉r das Quartal zum 30. Juni 2025 bekanntgegeben wurden, und gab ein Update zu seinem klinischen Entwicklungsfortschritt. Die Pressemitteilung wird als Exhibit 99.1 bereitgestellt; eine Inline-XBRL-Titelseite ist als Exhibit 104 beigef眉gt. In der Einreichung hei脽t es, dass die bereitgestellten Informationen, einschlie脽lich des Exhibit 99.1, nach Section 18 nicht als "filed" gelten und, sofern nicht ausdr眉cklich angegeben, nicht durch Verweis in andere Unterlagen nach dem Securities Act oder dem Exchange Act einbezogen werden.
Der Bericht ist von Melissa Tosca, Chief Financial Officer, unterzeichnet. Im Text des 8-K sind keine einzelnen Finanzposten oder klinischen Daten enthalten; f眉r die vollst盲ndigen Details ist das Exhibit 99.1 heranzuziehen.
| (Commission File Number) | (IRS Employer Identification No.) | ||||
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
| Title of each class: | Trading Symbol(s) | Name of each exchange on which registered: | ||||||||||||
| Exhibit Number | Title | |||||||
99.1 | Press Release of Kiora Pharmaceuticals, Inc., dated as of August 8, 2025 | |||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | |||||||
| KIORA PHARMACEUTICALS, INC. | ||||||||
| By: | /s/ Melissa Tosca | |||||||
| Melissa Tosca | ||||||||
| Chief Financial Officer | ||||||||
| (Principal financial and accounting officer) | ||||||||
| Date: August 8, 2025 | ||||||||
Source:
FAQ
What did Kiora (KPRX) disclose in the August 8, 2025 8-K?
Does the 8-K include the financial figures for Q2 2025?
Where can I find the press release referenced in the 8-K?
Is the information in the 8-K considered 'filed' under the Exchange Act?
Who signed the 8-K for Kiora Pharmaceuticals?
